Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.

Journal: Current breast cancer reports
Published Date: Oct 16, 2017

Abstract

PURPOSE OF THE REVIEW: To understand the evidence for extending adjuvant aromatase inhibitor (AI) therapy from 5 to 10 years in post-menopausal women with hormone receptor positive (HR+) breast cancer.

Authors

  • Stephen M Schleicher
    Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Maura N Dickler
    Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals